Research
Hormonal
Orlistat and Liraglutide are currently available medication options for long-term obesity treatment in Germany.
Clinicians can prescribe Orlistat or Liraglutide for patients needing long-term obesity management.
StrongSupportsmedium confidence
Als medikamentöse Therapieoption stehen aktuell in Deutschland der Lipaseinhibitor Orlistat sowie der GLP-1 Rezeptor-Agonist (GLP-1RA) Liraglutid zur medikamentösen Langzeittherapie der Adipositas zur Verfügung.
Why this rating
The claim is based on current clinical practice guidelines.
Source
Medikamentöse Adipositastherapie – Chancen und Perspektiven
Anne Lautenbach et al. · Adipositas - Ursachen Folgeerkrankungen Therapie · 2021
DOI 10.1055/a-1491-5805
reviewCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →